|
|
(18.191.240.243)
|
Users online: 8987
|
|
|
|
|
|
Ijournet
|
|
|
|
|
VTE Risk in Postmenopausal Women Receiving Oral and Non-Oral Hormone Therapy Systematic Review and Meta-Analysis Hameed Rafid Hadi Ministry of Public Health, Maysan Health Department Maysan governorate, Iraq Online published on 8 February, 2019. Abstract Hormone replacement therapy can improve the quality of life for women with hypo-oestrogenic symptoms. Many women are still prescribed oestrogen therapy to treat postmenopausal symptoms. Venous thromboembolism (VTE), either deep vein thrombosis or pulmonary embolism, is a main harmful effect of HT among postmenopausal women. We aim to evaluate the risk of VTE in postmenopausal women using hormonal therapy either oral or non-oral types. Systematic review of MEDLINE, Cochrane CENTRAL, EMBASE, and Clinical Trials.gov according to PRISMA guidelines. 22 studies were included in the metaanalyses (9 case-control studies, 9 cohort studies, and 4 randomized controlled trials). VTE risk was not increased with non-oral HT, including users of estrogens and estrogens plus progestins (OR 0.97 [0.9–1.06]), non-oral estrogen therapy (ET)-only (OR 0.95 [0.81–1.10]), and non-oral combined estrogen-progestin therapy (OR 0.92 [0.77–1.09]). The comparison of non-oral vs. oral HT showed increased VTE risk with oral HT (OR 1.66 [1.39–1.98]). Increase the risk of VTE in postmenopausal women who using oral HT versus non oral HT. Top Keywords Venous thromboembolism, VTE, hormonal therapy, HT, postmenopausl women. Top | |
|
|
|
|
║ Site map
║
Privacy Policy ║ Copyright ║ Terms & Conditions ║
|
|
742,225,561 visitor(s) since 30th May, 2005.
|
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
|
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.
|